Two Sigma Investments LP Purchases 17,760 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

Two Sigma Investments LP grew its position in Alto Neuroscience, Inc. (NYSE:ANRO) by 137.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 30,700 shares of the company’s stock after purchasing an additional 17,760 shares during the period. Two Sigma Investments LP’s holdings in Alto Neuroscience were worth $130,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ANRO. Rhumbline Advisers increased its stake in Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after acquiring an additional 6,812 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alto Neuroscience in the fourth quarter valued at approximately $74,000. Wellington Management Group LLP increased its position in shares of Alto Neuroscience by 27.2% during the fourth quarter. Wellington Management Group LLP now owns 77,146 shares of the company’s stock valued at $326,000 after acquiring an additional 16,510 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after acquiring an additional 3,139 shares during the period.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. Finally, HC Wainwright started coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They set a “buy” rating and a $10.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.40.

Alto Neuroscience Stock Down 2.0%

Shares of NYSE ANRO opened at $2.45 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The stock has a market capitalization of $66.33 million, a PE ratio of -1.05 and a beta of 1.93. Alto Neuroscience, Inc. has a one year low of $1.60 and a one year high of $17.55. The business’s fifty day moving average price is $2.42 and its 200-day moving average price is $3.23.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.06. On average, equities research analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.